<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954613</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-05.18</org_study_id>
    <nct_id>NCT03954613</nct_id>
  </id_info>
  <brief_title>Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease</brief_title>
  <official_title>Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease Receiving Donepezil, Memantine or Donepezil/Memantine Combination Therapy: Open-Labeled, Randomized, Phase IV, Superiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, it is aimed to compare the effects of cognitive exercises applied on long-term
      internet environment to the cognitive level of patients who received donepezil, memantine or
      donepezil / memantin combination therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in MOCA total score</measure>
    <time_frame>6-months</time_frame>
    <description>MOCA: Montreal - Cognitive Assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in GDS total score</measure>
    <time_frame>6-months</time_frame>
    <description>GDS (The Geriatric Depression Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ADAS-Cog total score</measure>
    <time_frame>6-months</time_frame>
    <description>ADAS-Cog: Alzheimer's Disease Assessment Scale- Cognitive Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CDR total score</measure>
    <time_frame>6-months</time_frame>
    <description>CDR: The Clinical Dementia Rating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in B-ADL total score</measure>
    <time_frame>6-months</time_frame>
    <description>B-ADL: The Bayer Activities of Daily Living Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clock drawing test</measure>
    <time_frame>6-months</time_frame>
    <description>The subject is asked to draw the face of a clock with all numbers and to set the hands for a specified time (hh:mm) and will be evaluated according to ability to draw.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Change</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil/Memantin Combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donepezil/Memantin Combination + Cognitive Exercises (BEYNEX Software)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donepezil Mono</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Donepezil Mono + Cognitive Exercises (BEYNEX Software)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Memantine Mono</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Memantine Mono + Cognitive Exercises (BEYNEX Software)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Ebicomb</intervention_name>
    <description>Combination product and combination product plus cognitive exercises will primarily be evaluated in this study</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <other_name>Donepezil-Memantine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 55-90 years old who were diagnosed with Alzheimer's Dementia and had
             no history of cerebrovascular disease during the last 6 months,

          -  Patients without other neurodegenerative diseases and secondary dementia diagnoses,

          -  Patients with MOCA score of between 13-18,

          -  Patients with at least primary school graduation,

          -  Patients who have had no CNS disease including trauma in the last year,

          -  Patients without a diagnosis of psychiatric disease,

          -  Patients with a tablet or PC with an internet connection,

          -  Patients agreeing to perform BEYNEX daily activity at least 5 times per week,

          -  Patients signing informed consent form.

        Exclusion Criteria:

          -  Patients who have hypersensitivity to study working drugs,

          -  Psychotic patients,

          -  Disabled patients with orthopedic dominant extremity,

          -  Patients with ICU follow-up due to trauma in the last 6 months,

          -  Patients with severe visual impairment or eye surgery,

          -  Patients who refuse to sign the informed consent form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Türker Şahiner, Prof Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Project Consultant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maltepe University Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Cognitive Exercises</keyword>
  <keyword>Internet</keyword>
  <keyword>Donepezil</keyword>
  <keyword>Memantin</keyword>
  <keyword>Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

